Welcome to our dedicated page for Cyclacel Phar Pr SEC filings (Ticker: CYCCP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CYCCP SEC filings page on Stock Titan aggregates regulatory documents for Cyclacel Pharmaceuticals, Inc., the issuer of the 6% Convertible Exchangeable Preferred Stock trading under symbol CYCCP on The Nasdaq Capital Market. These filings provide detailed information on the company’s oncology development activities, capital structure and corporate changes, and are a primary source for understanding the rights and risks associated with the preferred stock.
Investors can review Form 8-K current reports that describe material events such as private placements of Series F Convertible Preferred Stock and related series A, B and C common stock purchase warrants, warrant exchange agreements, amendments to preferred stock terms, and reverse stock splits of the common stock. Certain 8-K filings also discuss changes in the company’s independent registered public accounting firm and include the prior auditor’s statement that limited cash resources raised substantial doubt about the company’s ability to continue as a going concern.
Filings linked to CYCCP also cover shareholder approvals and strategic transactions. For example, an 8-K details the results of a special meeting where shareholders approved the issuance of Cyclacel common stock to FITTERS Diversified Berhad in connection with the acquisition of Fitters Sdn. Bhd., the potential issuance of more than 20% of the outstanding common stock under Nasdaq rules, and an amendment to change the corporate name to Bio Green Med Solution, Inc. Additional 8-K and 8-K/A filings note the adoption of an updated logo and reference the company’s new name and ticker symbol for its securities.
Registration statements such as the Form S-1 provide further context by registering shares of common stock underlying the Series F Preferred Stock and warrants, and by including business descriptions that characterize Cyclacel as a clinical-stage biopharmaceutical company focused on cancer medicines based on cell cycle, epigenetics, transcriptional regulation and mitosis biology. These documents often incorporate audited or reviewed financial statements and risk factor discussions.
On Stock Titan, AI-powered tools summarize key points from lengthy filings, highlight items relevant to CYCCP holders—such as dividend rights, conversion features, ownership limitations and subsequent amendments—and surface disclosures on liquidity, going concern language and major transactions. Real-time updates from EDGAR mean new 8-K, 10-Q, 10-K, S-1 and related filings appear promptly, enabling users to quickly see how Cyclacel’s preferred stock, common equity and corporate profile are described in its official SEC submissions.
Cyclacel Pharmaceuticals, Inc. Schedule 13G filed by Yap Kim Choy discloses beneficial ownership of 218,000 shares, representing 9.8% of the class. The filing states these shares are held with sole voting and dispositive power and that they were not acquired to change or influence control of the issuer. The statement identifies the filing as a Schedule 13G disclosure and includes a signature certifying the accuracy of the information.
Cyclacel Pharmaceuticals, Inc. Schedule 13G filed by Ong Yee Lung reports beneficial ownership of 218,000 shares of Cyclacel common stock, representing 9.8% of the class. The filer states sole voting and dispositive power over all 218,000 shares. The filing is submitted under Schedule 13G disclosures and includes a certification that the shares were not acquired to change or influence control of the issuer. Several items (group membership, holdings on behalf of others, and subsidiary/group identification) are marked Not Applicable.
Kua Khai Loon filed a Schedule 13G reporting beneficial ownership of 218,000 shares of Cyclacel Pharmaceuticals, Inc. common stock, representing 9.8% of the class. The filing shows sole voting and dispositive power over all 218,000 shares and classifies the filer as an individual (IN). The document states the securities were not acquired to change or influence control of the issuer. The filing includes issuer and filer addresses and the CUSIP 23254L876. The signature date on the filing is 08/18/2025 and the triggering event date is 07/28/2025.
Cyclacel Pharmaceuticals reporting persons Armistice Capital, LLC and Steven Boyd state they do not beneficially own any shares of Cyclacel common stock. The filing discloses 0 shares and 0% ownership, and explains that Armistice Capital acts as investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares. The statement clarifies that the Master Fund disclaims beneficial ownership because it lacks voting and dispositive power under its investment management agreement, while Armistice and Mr. Boyd may be deemed to possess voting and investment power through that agreement. The ownership percentages are calculated using 1,583,965 shares reported outstanding in the issuer's S-1.
Cyclacel Pharmaceuticals, Inc. furnished a current report to share that it issued a press release detailing its second quarter 2025 results. The company attached this press release as Exhibit 99.1 and designated the information under both results of operations and Regulation FD disclosure, indicating it is being provided for informational purposes rather than as a filed financial statement.
Cyclacel Pharmaceuticals disclosed that it is presenting audited consolidated financial statements for the quarter ended March 31, 2025 to satisfy the eligibility requirements of a registration statement on Form S-3. The filing indicates the company is providing its audited quarter-end financials and related notes so it meets the stated Form S-3 condition for shelf or registered offerings.
The report lists two exhibits: Exhibit 99.1 (the audited financial statements for the quarter) and Exhibit 104 (the cover page interactive XBRL data). The filing itself does not include income statement, balance sheet, or management discussion figures within the report text provided.
On 08/08/2025, investor David E. Lazar filed Amendment No. 2 to Schedule 13D for Cyclacel Pharmaceuticals, Inc. (CUSIP 23254L801). The filing states that, as of the close of business 08/05/2025, Lazar no longer beneficially owns any shares of Cyclacel’s common stock. Based on the company’s reported 1,583,965 shares outstanding as of 07/10/2025 (per the 07/30/2025 Form S-1), his ownership is now 0 shares / 0 %.
Accordingly, this amendment is designated as a final “exit” filing; all voting and dispositive powers are listed as zero. Exhibit 1 (not included here) details transactions within the past 60 days, but the cover page confirms that no shares remain. No other material agreements, legal proceedings, or changes were disclosed.
Schedule 13D/A (Amendment 1) for Cyclacel Pharmaceuticals (CYCC, CYCCP) updates the beneficial ownership of former CEO David E. Lazar.
- Current stake: 129,629 common shares, representing 8.18% of the 1,583,965 shares outstanding as of 10 Jul 2025.
- Recent corporate actions: Cyclacel effected a 1-for-15 reverse stock split on 7 Jul 2025; share numbers in this filing are post-split.
- Ownership changes: On 26 Feb 2025 Lazar converted his preferred stock to common and sold 194,628,820 common shares (pre-split) to a third-party investor. Earlier filings overstated the preferred shares he retained; this amendment corrects that error.
- Governance update: Lazar resigned as Chief Executive Officer effective 2 Apr 2025 but remains a significant shareholder with sole voting and dispositive power over the reported shares.
No group affiliation, financing source identified as PF (personal funds), and no legal proceedings or additional arrangements beyond those disclosed.